Point72 Hong Kong LTD Regenxbio Inc. Transaction History

Point72 Hong Kong LTD

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$12.89 - $20.82 $86,363 - $139,494	6,700 New	6,700 $120,000
Q3 2022 Nov 14, 2022	BUY	$22.29 - $35.04 $67,605 - $106,276	3,033 New	3,033 $80,000
Q2 2022 Aug 15, 2022	SELL	$19.35 - $35.04 $18,885 - $34,199	-976 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$24.62 - $34.31 $7,804 - $10,876	-317 Reduced 24.52%	976 $32,000
Q4 2021 Feb 14, 2022	BUY	$30.19 - $40.28 $39,035 - $52,082	1,293 New	1,293 $42,000

Q3 2021 Nov 15, 2021	SELL	$29.09 - $45.68 $54,980 - $86,335	-1,890 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$32.46 - $40.48 $61,349 - $76,507	1,890 New	1,890 $73,000
Q1 2020 May 15, 2020	SELL	$21.5 - $54.2 $12,255 - $30,894	-570 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$34.54 - $44.87 $19,687 - $25,575	570 New	570 $23,000
Q1 2019 May 15, 2019	SELL	$40.82 - $62.45 $5,020 - $7,681	-123 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$39.11 - $75.15 $4,810 - $9,243	123 New	123 $5,000

193

42M

80.6K

55.2K

Ticker RGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,230,000
Market Cap $458M
Description
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.